CN116831130A - Application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker - Google Patents
Application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker Download PDFInfo
- Publication number
- CN116831130A CN116831130A CN202310746981.3A CN202310746981A CN116831130A CN 116831130 A CN116831130 A CN 116831130A CN 202310746981 A CN202310746981 A CN 202310746981A CN 116831130 A CN116831130 A CN 116831130A
- Authority
- CN
- China
- Prior art keywords
- compound
- tetrazole
- mercapto
- methyl
- pathogenic bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000207199 Citrus Species 0.000 title claims abstract description 55
- 235000020971 citrus fruits Nutrition 0.000 title claims abstract description 55
- XOHZHMUQBFJTNH-UHFFFAOYSA-N 1-methyl-2h-tetrazole-5-thione Chemical compound CN1N=NN=C1S XOHZHMUQBFJTNH-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 241000196324 Embryophyta Species 0.000 claims abstract description 15
- 244000000005 bacterial plant pathogen Species 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 108010069584 Type III Secretion Systems Proteins 0.000 claims description 10
- 230000000443 biocontrol Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 239000003899 bactericide agent Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 241000589655 Xanthomonas citri Species 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 239000000575 pesticide Substances 0.000 claims description 3
- 239000005648 plant growth regulator Substances 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 230000012010 growth Effects 0.000 abstract description 14
- 206010059866 Drug resistance Diseases 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 230000007918 pathogenicity Effects 0.000 abstract description 7
- 230000007923 virulence factor Effects 0.000 abstract description 6
- 239000000304 virulence factor Substances 0.000 abstract description 6
- 230000008635 plant growth Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000002609 medium Substances 0.000 description 18
- 239000008223 sterile water Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 241000208125 Nicotiana Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 241001052560 Thallis Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- PVTHJAPFENJVNC-MHRBZPPQSA-N kasugamycin Chemical compound N[C@H]1C[C@H](NC(=N)C(O)=O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O PVTHJAPFENJVNC-MHRBZPPQSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000005897 Etoxazole Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 2
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000589634 Xanthomonas Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- FXVNBZGTAWLLNE-UHFFFAOYSA-N 1,3-thiazole;zinc Chemical compound [Zn].C1=CSC=N1 FXVNBZGTAWLLNE-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000563903 Bacillus velezensis Species 0.000 description 1
- 239000005739 Bordeaux mixture Substances 0.000 description 1
- 241000790236 Burkholderia anthina Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 1
- 239000005750 Copper hydroxide Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000005802 Mancozeb Substances 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- YXLXNENXOJSQEI-UHFFFAOYSA-L Oxine-copper Chemical compound [Cu+2].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 YXLXNENXOJSQEI-UHFFFAOYSA-L 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000018819 Protein Translocation Systems Human genes 0.000 description 1
- 239000005664 Spirodiclofen Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910001956 copper hydroxide Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AXKBOWBNOCUNJL-UHFFFAOYSA-M sodium;2-nitrophenolate Chemical compound [Na+].[O-]C1=CC=CC=C1[N+]([O-])=O AXKBOWBNOCUNJL-UHFFFAOYSA-M 0.000 description 1
- DTDSAWVUFPGDMX-UHFFFAOYSA-N spirodiclofen Chemical compound CCC(C)(C)C(=O)OC1=C(C=2C(=CC(Cl)=CC=2)Cl)C(=O)OC11CCCCC1 DTDSAWVUFPGDMX-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention belongs to the technical field of plant disease control, and particularly relates to application of 1-methyl-5-mercapto-1H-tetrazole in controlling citrus canker. The compound has strong inhibition effect on hpa1 gene promoter in a pathogenic bacteria III type secretion system, does not influence the normal growth of pathogenic bacteria, can strongly inhibit virulence factors of plant pathogenic bacteria while not influencing the growth of plant pathogenic bacteria, remarkably reduces the pathogenicity of plant pathogenic bacteria, and achieves the effect of preventing and treating citrus canker; the composition also has the effect of reducing the generation of drug resistance of pathogenic bacteria to the compound, and has longer effective service life in the aspect of controlling plant diseases, and wide application prospect.
Description
Technical Field
The invention belongs to the technical field of plant disease control. More particularly relates to the application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker.
Background
Citrus is the first major fruit in the world, and is also the most important fruit tree with the widest cultivation area and the most economic status in the south of China. Citrus canker is one of the most serious bacterial diseases on citrus, caused by the gram-negative bacterium citrus canker Xanthomonas citri subsp. The citrus canker is easy to prevent and treat, and once the citrus canker is infected, the citrus canker is toxic for life. In China, the average economic loss caused by citrus canker is as high as 5 hundred million yuan each year, and the healthy development of the citrus industry is greatly threatened. Therefore, the development of new effective disease control drugs is one of the key problems that need to be solved urgently.
Traditional antibiotics are usually targeted by the key factors of bacterial survival, but the long-term irregular use of antibiotics has made bacterial resistance more and more common and serious. In order to solve the problem of drug resistance, chinese patent application CN111713514A discloses a medicament for citrus canker, which is prepared by combining an organic copper bactericide, nano silver sol and plant volatile oil, and improves the sterilizing capability and delays the generation of drug resistance of pathogenic bacteria through the synergistic effect of the organic copper bactericide, the nano silver sol and the plant volatile oil. Although the method delays the generation of drug resistance, with long-term use, citrus canker bacteria gradually cause the generation of drug resistance of pathogenic bacteria according to the rule of being out of priority in the nature, and the long-term use is not facilitated.
Therefore, there is an urgent need to provide a method for controlling citrus canker, which has a good anti-citrus canker effect and does not cause the citrus canker to have drug resistance even after long-term use.
Disclosure of Invention
The invention aims to overcome the defect and the defect that the traditional method for preventing and treating the citrus canker is easy to cause the drug resistance of pathogenic bacteria, and provides the application of the 1-methyl-5-mercapto-1H-tetrazole in preventing and treating the citrus canker, so that the effects of good anti-citrus canker and no drug resistance of the citrus canker can be achieved after long-term use.
The invention aims to provide an application of 1-methyl-5-mercapto-1H-tetrazole as a plant pathogenic bacteria type III secretion system inhibitor.
Another object of the present invention is to provide a composition for controlling plant diseases.
The above object of the present invention is achieved by the following technical scheme:
the natural product is a treasury which is presented to human beings by nature, people can obtain prevention and treatment medicines, medical and agricultural antibiotics for curing diseases seriously endangering human health, develop efficient low-toxicity pesticides, plant growth hormone and other substances with economic value, and the natural product is environment-friendly. The inventor finds that the natural active product 1-methyl-5-mercapto-1H-tetrazole has remarkable control effect on citrus canker by inhibiting the expression of the hpa1 gene promoter in a plant pathogenic bacteria type III secretion system.
Therefore, the invention claims the application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker, wherein the 1-methyl-5-mercapto-1H-tetrazole is called compound Z-10 for short, and has the following structure:
the prevention and treatment is prevention and/or treatment, namely prevention and/or treatment of citrus canker, and can prevent plants from being affected by the citrus canker.
Further, the pathogenic bacteria of the citrus canker is citrus canker Xanthomonas citri subsp.
Still further, the compound Z-10 inhibits the plant pathogenic bacteria type III secretion system. The type III secretion system (T3 SS) is a key virulence factor in gram-negative pathogenic bacteria, and the expression of the main regulatory factors, hrpG and HrpX, the assembly of needle structures and the expression of effector proteins are the main causes of pathogenicity of such bacteria. The compound Z-10 acts on virulence factors of bacteria, takes the virulence factors as targets, reduces pathogenicity of the bacteria, does not influence normal growth of the bacteria, can achieve the effect of reducing drug resistance of the bacteria, and realizes long-term and effective prevention and control of citrus canker.
Further, the compound Z-10 inhibits the expression of the hpa1 gene promoter in a plant pathogenic bacteria type III secretion system.
Furthermore, the 1-methyl-5-mercapto-1H-tetrazole can be pharmaceutically acceptable salt or hydrate thereof, and the pharmaceutically acceptable salt or hydrate of the 1-methyl-5-mercapto-1H-tetrazole can be used as a precursor to achieve an activity similar to that of the 1-methyl-5-mercapto-1H-tetrazole.
Based on this, the invention also claims the use of 1-methyl-5-mercapto-1H-tetrazole, said 1-methyl-5-mercapto-1H-tetrazole being abbreviated as compound Z-10, as an inhibitor of the type III secretion system of phytopathogens, having the following structure:
further, the 1-methyl-5-mercapto-1H-tetrazole can be pharmaceutically acceptable salt or hydrate thereof, and the pharmaceutically acceptable salt or hydrate of the 1-methyl-5-mercapto-1H-tetrazole can be used as a precursor to achieve an activity effect similar to that of the 1-methyl-5-mercapto-1H-tetrazole.
Further, the inhibitor is in a solid preparation or a liquid preparation. Preferably, the solid formulation comprises a direct use solid formulation, a dispersible solid formulation, a soluble solid formulation; the liquid preparation comprises a liquid preparation, a dispersion liquid preparation, an emulsion preparation, a suspension preparation and a multiphase preparation.
In addition, the invention also provides a composition for preventing and treating plant diseases, which contains 1-methyl-5-mercapto-1H-tetrazole or pharmaceutically acceptable salt or hydrate thereof and one or more of bactericides, biocontrol bactericides, plant growth regulators and pesticides.
Further, the plant disease is citrus canker. The pathogenic bacteria of the citrus canker is citrus canker Xanthomonas citri subsp.
Preferably, the bactericide comprises: thiabendazole, oxine-copper, zinc thiazole, spring terramycin, mancozeb, copper hydroxide, bordeaux mixture and the like.
Preferably, the biocontrol microbial agents include bacillus subtilis, bacillus amyloliquefaciens, bacillus methylotrophicus and the like.
Preferably, the plant growth regulator comprises: gibberellin, benzylaminopurine, sodium nitrophenolate, brassin, and the like.
Preferably, the insecticide comprises: etoxazole, spirodiclofen, avermectin, etoxazole and the like.
The invention has the following beneficial effects:
the invention provides an application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker, which has a strong inhibition effect on hpa1 gene promoters in pathogenic bacteria type III secretion systems, does not influence normal growth of pathogenic bacteria, can strongly inhibit virulence factors of plant pathogenic bacteria while not influencing growth of the plant pathogenic bacteria, remarkably reduces pathogenicity of the plant pathogenic bacteria, and achieves the effect of preventing and treating citrus canker; the composition also has the effect of reducing the generation of drug resistance of pathogenic bacteria to the compound, and has longer effective service life in the aspect of controlling plant diseases, and wide application prospect.
Drawings
FIG. 1 is a graph showing the growth of Xcc jx-6 in NB medium or XVM medium after addition of Compound Z-10 in example 2 of this invention.
FIG. 2 is a graph showing the effect of compound Z-10 of example 4 of the present invention on tobacco HR after treatment with Xcc jx-6.
FIG. 3 is a graph showing the control of citrus canker by different concentrations of Compound Z-10 in example 5 of the present invention.
FIG. 4 is a graph showing the results of the coating of the number of Xcc jx-6 colonies in citrus leaves after inoculation with different concentrations of Compound Z-10 in example 5 of the present invention.
FIG. 5 is a graph showing the statistical results of the number of Xcc jx-6 colonies in citrus leaves after inoculation with different concentrations of compound Z-10 in example 5 of the present invention.
FIG. 6 is a graph showing the results of the coating of the number of Xcc jx-6 colonies in citrus leaves after the compound Z-10 of example 6 of the present invention was inoculated with biocontrol strain HN-8.
FIG. 7 is a graph showing the statistical result of the number of Xcc jx-6 colonies in citrus leaves after compound Z-10 and biocontrol strain HN-8 in example 6 of the present invention are inoculated.
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
The citrus canker caused by citrus canker pathogen (Xanthomonas citri subsp. Citri, xcc) is an important bacterial disease on citrus, and the development of novel and effective disease control novel medicines is one of the key problems which need to be solved urgently. The type III secretion system (T3 SS) is a key virulence factor of Xcc, is highly homologous and conserved in Xanthomonas, can reduce pathogenicity of the Xanthomonas when taking the T3SS as a target, reduces occurrence of diseases without affecting growth of the Xcc, can delay drug resistance of pathogenic bacteria to drugs, and is beneficial to long-term effective use of the drugs.
The following examples are examples of test compounds for inhibition of T3SS by citrus canker bacteria, test pathogenic bacteria: xcc wild-type strain Xcc jx-6, and strain Xcc jx-6 with a reporter plasmid (lux reporter system containing hpa1 promoter sequence, regulated by T33SS regulatory factor), mainly cause citrus canker. Compound Z-10 was dissolved in dimethyl sulfoxide (DMSO) to prepare a test solution at a concentration of 200 mM.
Reagents and materials used in the following examples are commercially available unless otherwise specified.
EXAMPLE 1 inhibition of the hpa1 Gene promoter in the T3SS System by Compound Z-10
1. The experimental method comprises the following steps:
xcc jx-6 of the reporter plasmid was streaked on NA plates, single colonies were picked up 2-3 days later and placed in NB medium, kanamycin (final concentration 50. Mu.g/mL) was added, and cultured at 28℃and 200rpm until OD was reached 600 About 1.0, cells were collected by centrifugation, and XVM culture medium (20 mM NaCl,10mM (NH 4)) 2 SO 4 ,5mM MgSO 4 ,1mM CaCl 2 ,0.16mM KH 2 PO 4 ,0.32mM K 2 HPO 4 ,0.01mM FeSO 4 10mM fructose, 10mM sucrose, 0.03% Casamino Acids, pH 6.7), and then re-suspended in XVM2 medium, kanamycin was added to adjust the OD 600 Adding compound Z-10 to a final concentration of 200 μm to 0.1, mixing thoroughly, and taking the same volume of DMSO as solvent as reference to obtain bacterial suspension containing the compoundSub-packaging into black 96-well plates with transparent bottoms, culturing XVM2 with the same volume as a background at 150 mu L of each well for subsequent calculation of inhibition rate, and setting 3 parallel per treatment; 96-well plates were treated at 28℃and 200rpm for 16h. Measuring self-luminescence value (LUX) and OD respectively with multifunctional enzyme-labeled instrument 600 After subtraction of the background value of XVM medium, inhibition of the compound was calculated using the formula. The calculation formula is as follows:
2. experimental results:
the results are shown in Table 1.
TABLE 1 inhibition of the hpa1 Gene promoter in T3SS System by Compounds Z-10
| Compounds of formula (I) | LUX/OD 600 | Inhibition rate% |
| DMSO | 1811.70±94.29 | - |
| Z-10 | 203.61±28.13* | 88.76 |
Note that: ", represents a significant difference compared to DMSO-treated group, indicating that the compound has a strong inhibitory effect on hpa1 promoter.
As can be seen from the table, the compound Z-10 has a strong inhibitory effect on the hpa1 promoter.
EXAMPLE 2 Effect of Compound Z-10 on growth of wild-type Strain Xcc jx-6
1. The experimental method comprises the following steps:
the growth curves for Xcc jx-6 in the presence of compound Z-10 in enriched NB and T3SS induction medium XVM2 were determined, respectively. Streaking and activating Xcc jx-6 wild strain on NA plate, picking single colony to NB culture medium after 2-3 days, growing to OD 600 About 1.0, cells were collected by centrifugation, resuspended in NB medium or XVM medium, and OD adjusted 600 To 0.1, compound Z-10 was added separately, mixed well to a final concentration of 200. Mu.M, placed in 96 well plates, and 3 replicates were set per treatment with equal volumes of DMSO as solvent control. Culturing at 28deg.C under 200rpm, measuring data (band plate cover) with multifunctional enzyme-labeled instrument every 4 hr, and measuring to 48 hr.
2. Experimental results:
the experimental results are shown in FIG. 1, wherein the left graph shows the growth curve of Xcc jx-6 in NB medium supplemented with Compound Z-10, and the right graph shows the growth curve of Xcc jx-6 in XVM medium supplemented with Compound Z-10. The results showed that compound Z-10 did not show significant inhibition of Xcc jx-6 growth in either NB medium or XVM2 medium during the slow, log and stationary phases of Xcc jx-6 growth as compared to control DMSO.
EXAMPLE 3 determination of Minimum Inhibitory Concentration (MIC) of Compound Z-10 for Xcc jx-6
1. The experimental method comprises the following steps:
xcc jx-6 Strain was cultured in NB Medium to OD 600 About 0.6 to 0.8, collecting the cells by centrifugation, re-suspending the cells with NB medium, and adjusting the OD 600 To 0.2, the concentration of the bacterial liquid is approximately 2X 10 8 CFU/mL, the bacterial suspension was diluted to 4X 10 in a ratio of 1:500 5 Concentration of CFU/mL; adding a certain volume of Z-10 mother liquor into diluted bacterial suspension, and fully and uniformly mixing to ensure that the initial compound concentration is 12800 mu M; spring day with initial concentration of 12800 mug/mL is used as positive reagent control; equal volume of DMSO plusInto the bacterial suspension as a solvent control; the same volume of NB medium without bacteria was used as a blank, and the compound concentration was diluted to 6.25. Mu.M or 6.25. Mu.g/mL (total 12 gradients) in 96-well plates by a 2-fold gradient dilution method, and left at 28℃for 1-2 days. And taking the turbidity of the solvent contrast as a reference standard, wherein in the compound Z-10 treatment group, the compound concentration corresponding to the clear bacterial liquid in the micropores is the Minimum Inhibitory Concentration (MIC).
2. Experimental results:
the results are shown in Table 2.
TABLE 2 determination of Minimum Inhibitory Concentration (MIC) of Compound Z-10 for Xcc jx-6
As can be seen from the table, the minimum inhibitory concentration of the compound Z-10 of the present invention on Xcc jx-6 was 743. Mu.g/mL.
EXAMPLE 4 Effect of Compound Z-10 on the allergic response (HR) of Xcc jx-6 on tobacco
1. The experimental method comprises the following steps:
xcc jx-6 strain was cultured in NB medium to OD 600 About 0.6 to 0.8, centrifugally collecting the thalli, re-suspending the thalli with sterile water, and adjusting the OD 600 To 0.5, compound Z-10 was added and mixed well to a final concentration of 200. Mu.M, treated with an equal volume of DMSO as a solvent control, sterile water as a blank (CK), and treated at 28℃for 2h. And then inoculating the treated Xcc jx-6 bacterial suspension to Benshi tobacco cultured in a greenhouse for two months by using a needleless injector, and continuously culturing the tobacco in the greenhouse after inoculation, and photographing and observing after 4-6 days.
2. Experimental results:
as a result of the experiment, referring to FIG. 2, it can be seen that compound Z-10 has a significant inhibitory effect on the HR of Xcc jx-6 on tobacco, a non-host plant.
Example 5 Effect of Compound Z-10 on the pathogenicity of Xcc Strain on citrus
1. The experimental method comprises the following steps:
the citrus is Wo-gan, and is cultivated in a greenhouse. Xcc jx-6 Strain was cultured in NB Medium to OD 600 About 0.6 to 0.8, centrifugally collecting the thalli, re-suspending the thalli with sterile water, and adjusting the OD 600 To 0.2 (1.0X10) 8 CFU/mL), compound Z-10 at final concentrations of 100. Mu.M, 150. Mu.M, 200. Mu.M, and kasugamycin at final concentrations of 200. Mu.M were added as positive reagent controls, equal volumes of DMSO as solvent controls, sterile water and sterile water containing 200. Mu.M compound Z-10 as blank controls. The compound and the bacterial liquid are fully and evenly mixed and treated for 2 hours at the temperature of 28 ℃. Taking 5-10 mu L of the treated bacterial suspension or sterile water, and extruding the bacterial suspension or sterile water into the back surface of the citrus leaves by using a 1mL needleless injector. And (5) continuously placing the strain in a greenhouse for culturing for 3-7 days after inoculation, and observing the disease condition.
2. Experimental results:
the results of inoculation are shown in FIG. 3. The right side of the veins are respectively from top to bottom: sterile water control, sterile water control for compound Z-10, dmso+wt (wild type Xcc jx-6 strain) solvent control, kasugamycin+wt positive agent control; two of the blank controls had no sign of onset at all, dmso+wt solvent control was normal onset, and a veramycin+wt positive agent control also showed significant plaque. The left side of the veins is respectively from top to bottom: compound Z-10+wt experiments at concentrations of 100 μm, 150 μm, 200 μm; it can be seen that compound Z-10 had significant lesions at a concentration of 100. Mu.M, significantly smaller lesions at a concentration of 150. Mu.M, and were completely non-pathogenic at a concentration of 200. Mu.M.
In order to more accurately count the control effect of the compound, the inventors cut out leaves with the diameter of 5mm by using a puncher with the diameter of 5mm and taking an inoculation point as a circle center, grind the leaves into homogenate by using sterile water in a mortar after sterilization, take 100 mu L to coat on an NA flat plate after gradient dilution to proper concentration, and culture the flat plate for 2-3 days at the temperature of 28 ℃ for colony counting. The coating results are shown in fig. 4, and the counting results are shown in fig. 5. The result shows that the compound Z-10 has very remarkable control effect on citrus canker at the concentration of 200 mu M compared with the control, and has better effect than the kasugamycin positive medicament at the same concentration.
EXAMPLE 6 Compound Z-10 and biocontrol Strain HN-8 have effect of controlling citrus canker
1. The experimental method comprises the following steps:
citrus variety: wo citrus reticulata (R) is used. Xcc jx-6 strain and biocontrol strain HN-8 (Burkholderia anthina HN-8, patent No. 201711405448.1) were cultured in NB medium to OD 600 About 0.6 to 0.8, collecting the cells by centrifugation, re-suspending the cells with sterile water, and subjecting the Xcc jx-6 to OD 600 Adjusted to 0.2 (1.0X10) 8 CFU/mL), the concentration of the compound Z-10 was selected to be 100. Mu.M with substantially no control effect, and the concentration of biocontrol strain HN-8 was selected to be pathogen Xcc jx-6OD 600 2 times the value, i.e. to OD 600 =0.4. The following experimental groups were set up: Z-10+WT, HN-8+WT, Z-10+HN-8+WT, DMSO+WT solvent control, sterile water as a blank, and treatment at 28℃for 2h. Taking 5-10 mu L of the treated bacterial suspension and sterile water, extruding the bacterial suspension and sterile water into the back of citrus leaves by a 1mL syringe without a needle, inoculating, continuously placing the citrus leaves in a greenhouse for culturing for 3-7 days, and observing the disease condition. And colony counting was performed on the inoculated portions with reference to the plating counting method in example 4.
2. Experimental results:
the coating results are shown in fig. 6, and the counting statistics are shown in fig. 7. Therefore, after 100 mu M of compound Z-10 without control effect is compounded with biocontrol strain HN-8, the effect is better than that of the compound Z-10 and biocontrol strain HN-8 which are singly used, and obvious synergistic effect is achieved, so that the compound Z-10 has good compounding potential.
In summary, the above examples all show that the compound Z-10, namely the compound 1-methyl-5-mercapto-1H-tetrazole, can strongly inhibit the expression of the hpa1 gene promoter of the T3SS system of the compound while not affecting the growth of pathogenic bacteria Xcc jx-6, thereby obviously reducing the pathogenicity of the pathogenic bacteria, and can achieve the effect of preventing and/or treating plant diseases caused by the pathogenic bacteria while not affecting the growth of the pathogenic bacteria, thereby avoiding the generation of drug resistance of the pathogenic bacteria and prolonging the effective service life of the compound.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (10)
- The application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker is characterized in that the 1-methyl-5-mercapto-1H-tetrazole is simply called a compound Z-10, and has the following structure:
- 2. use according to claim 1, wherein the pathogenic bacteria of citrus canker is citrus canker Xanthomonas citri subsp.
- 3. Use according to claim 2, characterized in that the compound Z-10 inhibits the plant pathogenic bacterial type III secretion system.
- 4. Use according to claim 3, characterized in that said compound Z-10 inhibits the expression of the hpa1 gene promoter in the secretory system of plant pathogenic bacteria type III.
- 5. The use according to any one of claims 1 to 4, wherein the 1-methyl-5-mercapto-1H-tetrazole is also a pharmaceutically acceptable salt or hydrate thereof.
- The application of 1-methyl-5-mercapto-1H-tetrazole as a plant pathogenic bacteria type III secretion system inhibitor is characterized in that the 1-methyl-5-mercapto-1H-tetrazole is simply called a compound Z-10, and has the following structure:
- 7. the use according to claim 6, wherein the 1-methyl-5-mercapto-1H-tetrazole is also in the form of a pharmaceutically acceptable salt or hydrate thereof.
- 8. The use according to claim 6 or 7, wherein the inhibitor is in the form of a solid or liquid formulation.
- 9. A composition for controlling plant diseases, which is characterized in that the composition contains 1-methyl-5-mercapto-1H-tetrazole or pharmaceutically acceptable salts or hydrates thereof and one or more of bactericides, biocontrol bactericides, plant growth regulators and pesticides.
- 10. The composition of claim 9, wherein the plant disease is citrus canker.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310746981.3A CN116831130A (en) | 2023-06-21 | 2023-06-21 | Application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310746981.3A CN116831130A (en) | 2023-06-21 | 2023-06-21 | Application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116831130A true CN116831130A (en) | 2023-10-03 |
Family
ID=88162728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310746981.3A Pending CN116831130A (en) | 2023-06-21 | 2023-06-21 | Application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116831130A (en) |
-
2023
- 2023-06-21 CN CN202310746981.3A patent/CN116831130A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0149672B1 (en) | Medical composition for the prophylaxis and treatment of clostridium difficile diarrhea and pseudomembranous colitis | |
| CN113367133B (en) | Application of cinnamic acid and derivatives thereof as antibacterial agent in inhibiting plant pathogenic bacteria | |
| CN110151752B (en) | Tea polyphenol composition and application thereof in preparation of anti-streptococcus suis medicines | |
| CN113040390B (en) | Probiotic salt-tolerant lactobacillus johnsonii and application thereof in preventing and treating pathogenic bacteria in livestock and poultry aquiculture | |
| CN109394598B (en) | Acne removing concentrate and application thereof | |
| CN114009443B (en) | Use of pleuromutilins for combating phytopathogenic bacteria | |
| Gong et al. | The specific effect of (R)-(+)-pulegone on growth and biofilm formation in multi-drug resistant Escherichia coli and molecular mechanisms underlying the expression of pgaABCD genes | |
| JP3019996B2 (en) | Ringworm treatment | |
| KR20140031048A (en) | Composition and method for exterminating scutica and pathogenic bacteria in fishes | |
| CN109526961B (en) | Application of cinnamic acid compound in preventing and/or treating plant diseases | |
| CN116831130A (en) | Application of 1-methyl-5-mercapto-1H-tetrazole in preventing and treating citrus canker | |
| CN116919998A (en) | Application of lactobacillus plantarum SHY21-2 in preventing and treating pathogenic bacteria infection and enhancing immunity in aquaculture | |
| CN110946857A (en) | Gallocatechin and its application in preparation of intestinal pathogenic bacteria medicine and feed additive | |
| CN113545349B (en) | Application of 1, 3-dicarbonyl-4-trifluoromethyl compound in resisting plant pathogenic bacteria | |
| CN114272246A (en) | Application of uracil in preparing anti-infective medicine | |
| Kumar | Adaptation of a blue-green alga to sodium selenate and chloramphenicol | |
| JP2007332110A (en) | Agent for controlling clubroot and method for controlling clubroot | |
| KR101903275B1 (en) | Novel microorganism lactobacillus plantarum cjl-159 or additives for fish feeds containing it | |
| CN111494363A (en) | Application of luteolin in resisting aeromonas hydrophila infection of aquatic animals | |
| CN109479878B (en) | Application of 2-methoxy phenylpropionic acid compound in preventing and/or treating plant diseases | |
| CN115067362B (en) | Sterilization composition containing rhodopseudomonas palustris and tricyclazole | |
| CN115386523B (en) | Lactococcus lactis and application thereof in resisting helicobacter pylori infection | |
| CN114392253B (en) | Use of allicin in preparing metallo-beta-lactamase inhibitor | |
| JP7458622B2 (en) | Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms | |
| CN108578400A (en) | Application of the nevadensin in preparing anti-candida albicans drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |